(-0.16%) 5 059.00 points
(-0.03%) 37 983 points
(-0.43%) 17 496 points
(-0.98%) $81.13
(-2.81%) $1.935
(-0.17%) $2 298.90
(0.30%) $26.74
(-0.39%) $944.50
(0.13%) $0.938
(0.24%) $11.12
(0.17%) $0.802
(-1.02%) $92.50
0.71% $ 1.420
Live Chart Being Loaded With Signals
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...
Stats | |
---|---|
Dzisiejszy wolumen | 706 536 |
Średni wolumen | 13 843.00 |
Kapitalizacja rynkowa | 4.55M |
EPS | $-4.50 ( 2023-08-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0722 |
ATR14 | $0.181 (28.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-06 | Hogan H Michael Iii | Buy | 0 | |
2023-06-30 | Maggio David | Buy | 0 | |
2023-01-29 | Gelone Steven P. | Sell | 140 | Ordinary Shares |
2023-01-29 | Schroeder Theodore R | Sell | 431 | Ordinary Shares |
2023-01-06 | Gelone Steven P. | Sell | 5 | Ordinary Shares |
INSIDER POWER |
---|
20.49 |
Last 98 transactions |
Buy: 1 927 900 | Sell: 612 376 |
Wolumen Korelacja
Nabriva Therapeutics PLC Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nabriva Therapeutics PLC Korelacja - Waluta/Towar
Nabriva Therapeutics PLC Finanse
Annual | 2022 |
Przychody: | $35.67M |
Zysk brutto: | $7.09M (19.87 %) |
EPS: | $-21.32 |
FY | 2022 |
Przychody: | $35.67M |
Zysk brutto: | $7.09M (19.87 %) |
EPS: | $-21.32 |
FY | 2021 |
Przychody: | $28.90M |
Zysk brutto: | $15.75M (54.50 %) |
EPS: | $-96.24 |
FY | 2020 |
Przychody: | $2.86M |
Zysk brutto: | $2.10M (73.25 %) |
EPS: | $-135.23 |
Financial Reports:
No articles found.
Nabriva Therapeutics PLC
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej